On Monday, Shares of Pfizer Inc. (NYSE:PFE), lost -0.55% to $34.56. The company exchanged hands with 27,551,643 shares as compared to its average daily volume of 26,196,300 shares. The company has the market capitalization of 212.81B.
Pfizer, declared that the U.S. Food and Drug Administration (FDA) has approved RAPAMUNE® (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive disease that affects the lungs, kidneys and the lymphatic system. This is the first approved treatment that assists stabilize lung function in patients with LAM.
LAM is a rare progressive lung disease that usually affects women during their childbearing years and can result in abnormal growth of smooth muscle cells in the lung. Over time, the muscle growth can cause airway obstructions and limit the delivery of oxygen to the body. About 800 patients in the U.S. are presently diagnosed with LAM, which is a rare disease and is often fatal. RAPAMUNE is also approved in the U.S. as an immunosuppressive agent for the prophylaxis of organ rejection in kidney transplant patients aged 13 years and older.
The FDA approval is based on the results from the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus or MILES Trial. The MILES Trial comprised of 89 LAM patients with moderate lung impairment and showed that those treated with RAPAMUNE for one year practiced stabilization of lung function measured by forced expiratory volume in one second (FEV1). The adverse drug reactions observed in this trial were compriseent with the known safety profile for renal transplant patients receiving RAPAMUNE, with the addition of weight reduced, which was stated at a greater incidence with RAPAMUNE as compared to placebo. Serious adverse events were stated more frequently during the treatment period in patients receiving RAPAMUNE contrast to the placebo group.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.
Shares of Melco Crown Entertainment Limited (NASDAQ:MPEL), declined -0.31% to $19.28, during its last trading session. The company exchanged hands with 3,513,791 shares as compared to its average daily volume of 3,622,040 shares. The company has the market capitalization of 10.39B.
The stock has price to sale ratio of 2.32, however, price to book ratio is 2.40. With recent decline, the year-to-date (YTD) performance reflected a -23.80% decline. During the past month the stock lose -5.41%, bringing three-month performance to -20.09% and six-month performance to -24.24%. The mean recommendation of analysts for this stock is 2.60. (where 1=Buy, 5=Sale).
Melco Crown Entertainment Limited, through its auxiliaries, develops, owns, and operates casino gaming and entertainment resort facilities in Asia. It owns and operates City of Dreams, an integrated casino resort that has 500 gaming tables and 1,400 gaming machines; about 1,400 hotel rooms and suites; a wet stage performance theater with about 2,000 seats; about 30 restaurants and bars, and 70 retail outlets; and recreation and leisure facilities, counting health and fitness clubs, swimming pools, spa and salons, and banquet and meeting facilities.
At the end of Monday’s trade, Shares of Abercrombie & Fitch Co. (NYSE:ANF), lost -0.34% to $20.40.
On May 22, Abercrombie & Fitch Co. stated that on May 21, 2015, the Board of Directors declared a quarterly cash dividend of $0.20 per share on the Class A Common Stock of Abercrombie & Fitch Co., payable on June 10, 2015 to shareholders of record at the close of business on June 2, 2015.
Abercrombie & Fitch Co., through its auxiliaries, operates as a specialty retailer of apparel for men, women, and kids. The company operates through three segments: U.S. Stores, International Stores, and Direct-to-Consumer.
Finally, Opko Health, Inc. (NYSE:OPK), ended its last trade with 3.56% gain, and closed at $18.31, hitting its highest level.
OPKO Health, declared that it has presented a New Drug Application (NDA) for oral Rayaldee to the U.S. Food and Drug Administration (FDA). The NDA requests marketing approval for Rayaldee for the prevention and treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
The Rayaldee application is supported by positive data from three randomized, double-blind, placebo-controlled studies and one open-label extension study conducted in the targeted patient population at a total of 105 U.S. sites. These studies met all primary efficacy and safety endpoints, as formerly declared.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
